Patient Selection for New nAMD and DME Therapies

EP: 1.Navigating Step Therapy in nAMD and DME

EP: 2.Role of Biosimilars in nAMD and DME Step Therapy

EP: 3.Overview of the Newest Therapies for AMD and DME: Faricimab and Aflibercept 8mg

EP: 4.Aligning Clinical Trial Retreatment Criteria to Clinical Practice

EP: 5.Perspectives on Retinal Fluid Management in nAMD and DME

EP: 6.Perspectives on Loading Dose and Treatment Extension With New Therapies

EP: 7.Using Steroids in DME Treatment

Now Viewing

EP: 8.Patient Selection for New nAMD and DME Therapies

EP: 9.Early Real-World Experiences With Faricimab and Aflibercept 8mg

EP: 10.Safety Considerations for New Therapies

EP: 11.Promoting Treatment Adherence in nAMD and DME

Summary

In the provided transcript, the physicians discuss the use of newer agents, such as faricimab and high-dose aflibercept, in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). They mention that these agents were primarily tested in treatment-naive patients but are also being used in refractory patients who have not responded well to other anti-VEGF treatments. The physicians describe two main scenarios for using these agents: switching patients who are not doing well on their current treatment to a newer agent and attempting to further extend treatment intervals in patients who are responding well but still require frequent injections. They emphasize the importance of individualized treatment approaches and monitoring patient response closely. Additionally, they discuss their experiences with different treatment strategies, including switching between agents and adjusting dosing intervals, based on patient needs and response. The physicians also touch upon the safety profile of these newer agents, highlighting the need for vigilance, especially in the case of brolucizumab, and expressing confidence in the safety of faricimab and high-dose aflibercept based on clinical trial data.

This summary was AI-generated and edited for clarity.